Skip to main content
Premium Trial:

Request an Annual Quote

DxS Gets CE-IVD Mark for TheraScreen Test on Roche's LightCycler

NEW YORK (GenomeWeb News) – Molecular diagnostics developer DxS has received European Union approval to sell its TheraScreen K-RAS Mutation Kit for use on Roche's LightCycler 480 Instrument II.

DxS said that the CE-IVD Mark will enable the firm to sell the test, which is used to monitor patient response to Amgen's panitumumab (Vectibix) and Merck's cetuximab (Erbitux) drugs for colorectal cancer, in clinical settings in the EU.

In addition, DxS said today that it has licensed Roche's LightCycler Adapt Software v1.1 to be used with the TheraScreen test kits. It said that the software will offer automated processing of K-RAS mutation status tests for colorectal cancer patients.

Manchester, UK-based DxS said that the software will be available for installation in territories where the K-RAS Mutation Kit is available for sale through Roche, including Europe, Saudi Arabia, South Africa, and Australia.

Financial terms of the agreement were not released.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.